Abstract
Myasthenia gravis (MG) is an autoimmune disease that results from antibody mediated damage of Acetylcholine receptor (AChR) at the neuromuscular junction. The autoimmune character of MG and pathogenic role of AChR antibodies have been established by several workers i.e., the demonstration of anti-AChR antibodies in about 90 % of MG patients. It has been demonstrated that patients with MG also have antibodies against a second protein named presynaptic membrane receptor (PsmR), which is identified by utilizing β-Bgtx, a ligand which binds to PsmR. Using β-Bgtx Sepharose 4B affinity matrix, the PsmR was purified from different regions of human cadaver brain by affinity chromatography. Purified receptor was characterized both by biochemical and immunological procedures. PsmR purified from different regions of the brain shows a specific activity of 0.37 ± 0.01, 0.39 ± 0.02 and 0.43 ± 0.005 nM/ μg of protein in Parietal lobe, Occipital lobe and Frontal lobe respectively. The affinity purified PsmR from the brain of 87 and 68 kd (parietal lobe, occipital lobe and frontal lobe) shows immunoreactivity with myasthenic sera. These findings suggest that PsmR from brain is another antigen against which autoantibodies are developed in Myasthenia gravis patients. Upon treatment with various enzymes we concluded that PsmR from brain is a glycoprotein in which the immunoreactivity resides in the carbohydrate as well as the peptide epitopes. In conclusion the PsmR is another antigen against which autoantibodies are formed in different regions of brain. These can be used as a diagnostic tool for detecting antibodies in the sera or cerebrospinal fluid of MG patients.
Similar content being viewed by others
References
Aarli JA, Lefvert AK, Tonder O. Thymoma-specific antibodies in sera from patients with myasthenia gravis demonstrated by indirect haemagglutination. J Neuroimmunol. 1981;1(4):421–7.
Brenner T, Abramsky O, Lisak RP, Zweiman B, Tarab-Hazdai R, Fuchs S. Radio-immunoassay of antibodies to acetylcholine receptor in serum of myasthenia gravis patients. Isr J Med Sci. 1978;14(9):986–9.
Chang CE, Lee CY. Isolation of neurotoxins from the venom of Bungarus multicinctus and their modes of neuromuscular blocking action. Arch Pharmacodyn Ther. 1962;144:241–57.
Chaun-Zhen L. Anti-presynaptic membrane receptor antibodies in myasthenia gravis. J Neurol Sci. 1991;102:39–45.
Clarke PBS, Reuben M. Release of (3H)noradrenaline from rat hippocampal synaptosomes by nicotine: mediation by different nicotinic receptor subtypes from striatal (3H)dopamine release. Br J Pharmacol. 1996;117:595–606.
Conti-Tronconi BM, Raftery MA. The nicotinic cholinergic receptor: correlation of molecular structure with functional properties. Ann Rev Biochem. 1982;51:491–530.
Decker MW, Brioni ID, Bannon AW, Arneric SP. Diversity of neuronal nicotinic acetylcholine receptors: lessons from behavior and implications for CNS therapeutics. Life Sci. 1995;56(8):545–70.
Drachman DB, Angus CW, Adams RN, Michelson JD, Hoffman GJ. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N Engl J Med. 1978;298:1116–22.
Dwyer DS, Bradly RJ. Antibodies against nicotinic acetylcholine receptor in myasthenia gravis. Clin Exp Immunol. 1979;37(3):448–51.
Fambrough DM, Drachman DB, Satyamurti S. Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors. Science. 1973;182(1 09):293–5.
Gottic C, Conti-Tronconi BM, Raftry MA. Mammalian muscle acetylcholine receptor. Purification and characterization. Biochemistry. 1982;21(13):3148–54.
Hedqvist P, Moawad A. Presynaptic alpha- and beta-adrenoceptor medicated control of noradrenaline release in human oviduct. Acta Physiol Scand. 1975;95(4):494–6.
Hinman CL, Hudson RA, Burek CL, Goodlow G, Rauch HC. An enzyme-linked immunosorbent assay for antibody against acetylcholine receptor. J Neurosci Methods. 1983;9(2):141–55.
Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7(3):365–8.
Jailkhani BL, Asthana D, Jaffery NF, Subbalaxmi B. Alpha bungarotoxin aggregates on iodination with chloramine T but not with iodogen. J Neurol Immunol. 1984;6:337–45.
Jailkhani BL, Asthana D, Jaffery NF, Subbalaxmi KB, Ahuja GK. Elisa for detection of IgG and IgM Ab’s to nAChR in MG. Ind J Med Res. 1986;83:187–95.
Jailkhani BL, Asthana D, Jaffery NF, Kumar R, Ahuja GK. A simplified ELISA for antireceptor antibodies in MG. J Immunol Meth. 1986;86:115–8.
Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227(5259):680–5.
Lefvert AK, Bergstrom K. Acetylcholine receptor antibody in myasthenia gravis: purification and characterization. Scand J Immunol. 1978;8(96):525–33.
Lennon VA, Lindstorm LM, Seybold ME. Experimental autoimmune myasthenia gravis: cellular and humoral immune responses. Ann N Y Acad Sci. 1976;274:283–99.
Lindstorm JM. Autoimmune response to acetylcholine receptor. Adv Immunol. 1979;27:1–50.
Lindstorm JM, Seybold ME, Lennon VA, Shithnigam S, Duane DD. Antibody to AChR in MG prevalance, clinical correlates and diagnostic value. Neurology. 1976;26:1054–9.
Link H. Myasthenia gravis: T and B cell reactivities to the β-bungarotoxin binding protein presynaptic membrane receptor. J Neurol Sci. 1992;109:173–81.
Lowry OH, Rosenbrough NJ, Farra AL, Randall RJ. Protein measurement with Folin-phenol reagent. J Biol Chem. 1951;193(1):265–75.
Lu CZ, Lu L, Hao ZS, Xia DG, Qain J, Arnason BG. Antibody-secreting cells to acetylcholine receptor and to presynaptic membrane receptor in seronegative myasthenia gravis. J Neuroimmunol. 1993;43(1–2):145–9.
Patrick J, Lindstorm J. Autoimmune response to acetylcholine receptor. Science. 1973;180(88):871–2.
Pestronk A. Intracellular acetylcholine receptor in skeletal muscle of adult rat. J Neurosci. 1985;5(5):1111–7.
Qiao J. β-Bungarotoxin binding protein is immunogenic but lacks myasthogenicity in rats. J Neurol Sci. 1994;121:190–3.
Rasool S, Jailkhani BL, Irshad M, Behari M, Suhail S, Shabirul H. Purification of beta bungarotoxin (β-Bgtx) binding protein from human cadaver skeletal muscle. J Med Sci. 2007;7:195–202.
Rasool S, Behari M, Irshad M, Goyal V, Jailkhani BL. Antibodies against postsynaptic acetylcholine receptor and presynaptic membrane receptor in myasthenia gravis. Trends Med Res. 2008;3:64–71.
Sanders DB, Howard JF Jr. Disorders of neuromuscular transmission. In: Bradley WG, Daroff RB, Fenichel GM, et al., editors. Neurology in clinical practice, the neurological disorders. Philadelphia: Butterworth Heinemann; 2004. p. 2441–61.
Schmidt RR, Betz H. The β-Bgtx binding protein from chicken brain biding sites for different neuronal K+ channel ligands co-factors upon partial purification. FEBS Lett. 1988;340:65–70.
Skeie O, Romi F, Aarli JA, et al. Pathogenesis of myositis and myasthenia associated with titin and ryanodine receptor antibodies. Ann N Y Acad Sci. 2003;998:343–50.
Somnier FE, Engel PJ. The occurrence of anti-titin antibodies and thymomas: a population survey of MG 1970–1999. Neurology. 2002;59:92–8.
Toyka KV, Drachman DB, Griffin DE, Pestronk A, Winkelstein JA, Fishbeck KH, et al. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med. 1977;296(3):125–31.
Vincent A, Leite MI. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr Opin Neurol. 2005;18(5):519–25.
Vincent A, Newsom-Davis J. Alpha-bungarotoxin and anti-acetylcholine receptor antibody binding to human acetylcholine receptor. In: Ceccarelli B, Clementi F, editors. Advance’s in cytopharmacology. Neurotoxins-tools in neurobiology, vol. 3. New York: Raven; 1979. p. 267–78.
Vincent A, Newsome D. Acetylcholine receptor antibody as a diagnostic test for MG. J Neuro Neurosurg Psychiatry. 1985;48:1246–52.
Wiedenmann B, Franke WW. Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles. Cell. 1985;41(3):1017–28.
Xiao B-G. Immunological specificity and cross reactivity of anti-acetylcholine receptor and anti-presynaptic membrane receptor antibodies in myasthenia gravis. J Neurol Sci. 1991;105:118–23.
Yi Q, Pirskanen R, Lefvert AK. Presynaptic membrane receptor-reactive T lymphocytes in myasthenia gravis. Scand J Immunol. 1996;43(1):81–7.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rasool, S., Behari, M., Goyal, V. et al. Presynaptic Membrane Receptor in Human Brain. Ind J Clin Biochem 28, 124–135 (2013). https://doi.org/10.1007/s12291-012-0248-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12291-012-0248-1